Session Information
Session Type: Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Systemic lupus erythematosus is a chronic inflammatory disorder that significantly burdens our health system. The study aimed to understand the difference in in-patient outcomes based on insurance status, especially between Medicare and non-Medicare groups.
Methods: Using National Inpatient Sample databases from 2016 – 2020, we identified patients with underlying systemic lupus erythematosus. Patients were divided into two main groups (with Medicare and with non-Medicare insurance). Our primary outcome of the study was in-patient mortality, length of stay and hospital cost. Multivariate logistic regression, and student t-test were used for analysis using STATA 17.0.
Results: Out of 789,720 SLE admissions, 49.9% were non-Medicare, and 51.1% had Medicare as an insurance. Medicare cohort were older (mean age 62±15.0 vs 44±14.2, P value < 0.001) and predominantly Caucasians compared to Non-Medicare cohort. Medicare cohort was associated with a higher prevalence of Hypertension (74.7% vs 50.4, P value < 0.001), peripheral vascular disease (10.1% vs 4.5%, P value < 0.001), chronic kidney disease (32.4% vs 16.6%, P value < 0.001) and Congestive heart failure (29.5% vs 14.5%, P value < 0.001) when compared to a non-Medicare cohort. However, there were fewer patients with Obesity in Medicare cohort when compared to the non-Medicare cohort (19.1% vs 20.6%, P value < 0.001). In-patient mortality between Medicare and non-Medicare group (10090 vs 6075, OR 0.76, 95% CI 0.68-0.84 P value < 0.001) showed significant better outcome in non-Medicare group. There was higher in-hospital cost in Medicare cohort compared to non-medicare cohort ($17475 vs $17128, P value < 0.001) and slightly longer length of stay in Medicare cohort compared to non-medicare cohort (5.5±6.1 vs 5.2±7.1, P value < 0.001).
Conclusion: This study shows that having a Non-medicare payer is better than Medicare. However, the difference is minimal even though it is statistically significant, so we should assess the clinically significant difference between the two cohorts.
To cite this abstract in AMA style:
Paul M, Paul P, Amgai B, Ramos J. In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/in-patient-outcome-difference-in-systemic-lupus-erythematous-patient-between-medicare-and-non-medicare-group-a-nationwide-analysis/. Accessed .« Back to ACR Convergence 2023
ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-patient-outcome-difference-in-systemic-lupus-erythematous-patient-between-medicare-and-non-medicare-group-a-nationwide-analysis/